Biotechnology
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
TOKYO, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficient drug discov...
2026-05-11 08:00
1526
ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
SEOUL, South Korea, May 11, 2026 /PRNewswire/ -- ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines. Centered on customer value and empowering global biopharmaceutical innovation, the upgrade simplifies compliance workflows to support efficien...
2026-05-11 08:00
1461
AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest
ROCKVILLE, Md., May 8, 2026 /PRNewswire/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production system, designed to improve AAV vector productivity, full-capsid yield, manufacturing efficiency, and...
2026-05-08 20:26
4093
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review ...
2026-05-08 19:29
3887
Men can step up to domestic duties to help arrest the global backslide in birth rates
BEIJING, May 8, 2026 /PRNewswire/ -- A more active role for men in fatherhood and domestic chores could be the key lever of population rebound to arrest collapsing fertility rates around the world. Men being more hands-on in infant care and household responsibilities can support family buildin...
2026-05-08 12:03
2558
ABEC Expands Process Sciences Group to Strengthen Bioprocess Optimization Capabilities
BETHLEHEM, Pa., May 6, 2026 /PRNewswire/ -- ABEC, a global leader in bioprocess engineering solutions, announced the expansion of itsProcess Sciences group, expanding its ability to help biopharmaceutical manufacturers accelerate development, reduce risk, and improve productivity across the biopr...
2026-05-06 22:09
2578
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry ...
2026-05-06 08:28
3045
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHD HOUSTON, May 5, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, ...
2026-05-05 05:16
2607
XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway
SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has succes...
2026-05-04 08:19
3670
Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025
AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform QINGDAO, China, April 30, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medi...
2026-04-30 12:35
4021
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include: * 2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months * 2L+ colorectal cancer (CRC): ORR of 46.9%, mPFS of 9.5 months ...
2026-04-30 11:20
4211
ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partne...
2026-04-30 08:30
3935
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentat...
2026-04-30 08:10
3434
ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, announces its collaboration with Carterra, a company focused on innovative technologies designed to accelerate the discovery...
2026-04-30 08:00
3039
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
* TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. * OPTIMAL-PSMA[2] initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification....
2026-04-30 05:00
4130
Infinitus Presents Human Evidence-Based Research Findings at FFC 2026
GUANGZHOU, China, April 30, 2026 /PRNewswire/ -- Ma Jun, Vice President and Chief Science Innovation Officer of Infinitus (China) Company Ltd., was invited to attend the Functional Food Conference 2026 (FFC 2026), held recently in Hangzhou, Zhejiang Province, where he delivered a keynote presenta...
2026-04-30 02:14
3440
Navinci launches Omni kit - the next generation of spatial interactomics
UPPSALA, Sweden, April 29, 2026 /PRNewswire/ -- Navinci today announces the launch ofOmni, breakthrough fully customized kits designed to transform how scientists study protein function directly in tissue. Omni provides cutting-edge spatial interactomics capabilities, enabling researchers to map ...
2026-04-29 22:32
3759
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
ANDERNACH, Germany, April 29, 2026 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solu...
2026-04-29 19:00
2953
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar ...
2026-04-29 18:08
3083
HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California
SINGAPORE, April 28, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers...
2026-04-28 15:30
4510
Week's Top Stories
Most Reposted
Visa Destinations Launches in Asia Pacific as Regional Travel Remains Resilient
[Picked up by 331 media titles]
2026-05-05 10:01Agoda Makes it Easier for Travelers to See Relevant Photos in Reviews
[Picked up by 313 media titles]
2026-05-06 12:00
AVPN AI Opportunity Fund Expands to Build AI-Ready Generations Across Asia by Empowering Educators and Youth Across Asia-Pacific
[Picked up by 298 media titles]
2026-05-05 09:00Colebrook Bosson Saunders Expands Flo X Multi Compatibility for Curved Ultrawide Monitors
[Picked up by 290 media titles]
2026-05-05 11:00
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 289 media titles]
2026-05-11 16:20
Most Read
Visa Destinations Launches in Asia Pacific as Regional Travel Remains Resilient
2026-05-05 10:01
7901
Amadeus delivers solid Q1 2026 growth, and maintains commercial momentum
2026-05-08 18:30
6926
Massimo Group Launches Sentinel 770 HVAC as Part of Sentinel Product Line Targeting Approximately US$10 Million in 2026 Revenue
2026-05-06 21:20
6893
LightInTheBox to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
2026-05-06 20:00
6661
